Evotec AG (NASDAQ:EVO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Evotec AG (NASDAQ:EVO) have been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.00.

EVO has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Berenberg Bank started coverage on Evotec in a research note on Tuesday. They issued a “buy” rating on the stock.

Evotec Stock Performance

EVO stock opened at $3.42 on Tuesday. The firm’s fifty day moving average is $3.31 and its 200 day moving average is $3.55. Evotec has a 52 week low of $2.84 and a 52 week high of $4.80. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Valeo Financial Advisors LLC bought a new stake in shares of Evotec during the 2nd quarter valued at $43,000. BNP Paribas Financial Markets boosted its stake in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after acquiring an additional 4,600 shares in the last quarter. Bank of America Corp DE grew its holdings in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Thrivent Financial for Lutherans bought a new position in shares of Evotec during the third quarter valued at approximately $53,000. Finally, XTX Topco Ltd purchased a new position in shares of Evotec during the second quarter valued at approximately $66,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.